Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.

INTRODUCTION: The overall survival rate is good for lymph-node-negative breast cancer patients, but they still suffer from serious over- and some undertreatments. Prognostic and predictive gene signatures for node-negative breast cancer have a high number of genes related to proliferation. The progn...

Full description

Bibliographic Details
Main Authors: Kristin Jonsdottir, Jörg Assmus, Aida Slewa, Einar Gudlaugsson, Ivar Skaland, Jan P A Baak, Emiel A M Janssen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3944091?pdf=render
_version_ 1818059804652863488
author Kristin Jonsdottir
Jörg Assmus
Aida Slewa
Einar Gudlaugsson
Ivar Skaland
Jan P A Baak
Emiel A M Janssen
author_facet Kristin Jonsdottir
Jörg Assmus
Aida Slewa
Einar Gudlaugsson
Ivar Skaland
Jan P A Baak
Emiel A M Janssen
author_sort Kristin Jonsdottir
collection DOAJ
description INTRODUCTION: The overall survival rate is good for lymph-node-negative breast cancer patients, but they still suffer from serious over- and some undertreatments. Prognostic and predictive gene signatures for node-negative breast cancer have a high number of genes related to proliferation. The prognostic value of gene sets from commercial gene-expression assays were compared with proliferation markers. METHODS: Illumina WG6 mRNA microarray analysis was used to examine 94 fresh-frozen tumour samples from node-negative breast cancer patients. The patients were divided into low- and high-risk groups for distant metastasis based on the MammaPrint-related genes, and into low-, intermediate- and high-risk groups based on the recurrence score algorithm with genes included in Oncotype DX. These data were then compared to proliferation status, as measured by the mitotic activity index, the expressions of phosphohistone H3 (PPH3), and Ki67. RESULTS: Kaplan-Meier survival analysis for distant-metastasis-free survival revealed that patients with weak and strong PPH3 expressions had 14-year survival rates of 87% (n=45), and 65% (n=49, p=0.014), respectively. Analysis of the MammaPrint classification resulted in 14-year survival rates of 80% (n=45) and 71% (n=49, p=0.287) for patients with low and high risks of recurrence, respectively. The Oncotype DX categorization yielded 14-year survival rates of 83% (n=18), 79% (n=42) and 68% (n=34) for those in the low-, intermediate- and high-risk groups, respectively (p=0.52). Supervised hierarchical cluster analysis for distant-metastasis-free survival in the subgroup of patients with strong PPH3 expression revealed that the genes involved in Notch signalling and cell adhesion were expressed at higher levels in those patients with distant metastasis. CONCLUSION: This pilot study indicates that proliferation has greater prognostic value than the expressions of either MammaPrint- or Oncotype-DX-related genes. Furthermore, in the subgroup of patients with high proliferation, Notch signalling pathway genes appear to be expressed at higher levels in patients who develop distant metastasis.
first_indexed 2024-12-10T13:22:21Z
format Article
id doaj.art-d2d5d384a54c41788b57b12b8c5904fc
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-10T13:22:21Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-d2d5d384a54c41788b57b12b8c5904fc2022-12-22T01:47:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0193e9064210.1371/journal.pone.0090642Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.Kristin JonsdottirJörg AssmusAida SlewaEinar GudlaugssonIvar SkalandJan P A BaakEmiel A M JanssenINTRODUCTION: The overall survival rate is good for lymph-node-negative breast cancer patients, but they still suffer from serious over- and some undertreatments. Prognostic and predictive gene signatures for node-negative breast cancer have a high number of genes related to proliferation. The prognostic value of gene sets from commercial gene-expression assays were compared with proliferation markers. METHODS: Illumina WG6 mRNA microarray analysis was used to examine 94 fresh-frozen tumour samples from node-negative breast cancer patients. The patients were divided into low- and high-risk groups for distant metastasis based on the MammaPrint-related genes, and into low-, intermediate- and high-risk groups based on the recurrence score algorithm with genes included in Oncotype DX. These data were then compared to proliferation status, as measured by the mitotic activity index, the expressions of phosphohistone H3 (PPH3), and Ki67. RESULTS: Kaplan-Meier survival analysis for distant-metastasis-free survival revealed that patients with weak and strong PPH3 expressions had 14-year survival rates of 87% (n=45), and 65% (n=49, p=0.014), respectively. Analysis of the MammaPrint classification resulted in 14-year survival rates of 80% (n=45) and 71% (n=49, p=0.287) for patients with low and high risks of recurrence, respectively. The Oncotype DX categorization yielded 14-year survival rates of 83% (n=18), 79% (n=42) and 68% (n=34) for those in the low-, intermediate- and high-risk groups, respectively (p=0.52). Supervised hierarchical cluster analysis for distant-metastasis-free survival in the subgroup of patients with strong PPH3 expression revealed that the genes involved in Notch signalling and cell adhesion were expressed at higher levels in those patients with distant metastasis. CONCLUSION: This pilot study indicates that proliferation has greater prognostic value than the expressions of either MammaPrint- or Oncotype-DX-related genes. Furthermore, in the subgroup of patients with high proliferation, Notch signalling pathway genes appear to be expressed at higher levels in patients who develop distant metastasis.http://europepmc.org/articles/PMC3944091?pdf=render
spellingShingle Kristin Jonsdottir
Jörg Assmus
Aida Slewa
Einar Gudlaugsson
Ivar Skaland
Jan P A Baak
Emiel A M Janssen
Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
PLoS ONE
title Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
title_full Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
title_fullStr Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
title_full_unstemmed Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
title_short Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
title_sort prognostic value of gene signatures and proliferation in lymph node negative breast cancer
url http://europepmc.org/articles/PMC3944091?pdf=render
work_keys_str_mv AT kristinjonsdottir prognosticvalueofgenesignaturesandproliferationinlymphnodenegativebreastcancer
AT jorgassmus prognosticvalueofgenesignaturesandproliferationinlymphnodenegativebreastcancer
AT aidaslewa prognosticvalueofgenesignaturesandproliferationinlymphnodenegativebreastcancer
AT einargudlaugsson prognosticvalueofgenesignaturesandproliferationinlymphnodenegativebreastcancer
AT ivarskaland prognosticvalueofgenesignaturesandproliferationinlymphnodenegativebreastcancer
AT janpabaak prognosticvalueofgenesignaturesandproliferationinlymphnodenegativebreastcancer
AT emielamjanssen prognosticvalueofgenesignaturesandproliferationinlymphnodenegativebreastcancer